Compare AVXL & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | SAR |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.7M | 372.7M |
| IPO Year | 2013 | N/A |
| Metric | AVXL | SAR |
|---|---|---|
| Price | $4.49 | $23.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $22.00 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 1.2M | 122.6K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $21.10 |
| 52 Week High | $13.99 | $26.17 |
| Indicator | AVXL | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 52.58 |
| Support Level | $3.60 | $22.39 |
| Resistance Level | $4.88 | $23.72 |
| Average True Range (ATR) | 0.27 | 0.49 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 78.01 | 71.15 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.